Practical aspects and considerations when switching between continuous subcutaneous insulin infusion and multiple daily injections

Diabetes Technology and Therapeutics

Volumn 12, Issue SUPPL. 1, 2010, Pages

  Meneghini, Luigi ^a   Sparrow Bodenmiller, Jane ^b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; INSULIN; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO;

ACUTE DISEASE; BASAL METABOLIC RATE; BLOOD GLUCOSE MONITORING; CONTINUOUS INFUSION; DIABETES MELLITUS; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG MEGADOSE; DRUG USE; EXERCISE; FOOD AND DRUG ADMINISTRATION; GLYCEMIC CONTROL; HOSPITAL MANAGEMENT; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; INSULIN PUMP; INTERMETHOD COMPARISON; PRIORITY JOURNAL; REVIEW;

BLOOD GLUCOSE; DIABETES MELLITUS; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN; INSULIN INFUSION SYSTEMS; NEEDLES; PATIENT EDUCATION AS TOPIC;

EID: 77956159186     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/dia.2009.0184     Document Type: Review

References (46)

1. DeVries JH, Snoek FJ, Kostense PJ, Masurel N, Heine RJ, the Dutch Insulin Pump Study Group: A randomized trial of continuous subcutaneous insulin infusion and intensive injection therapy in type 1 diabetes for patients with longstanding poor glycemic control. Diabetes Care 2002;25:2074-2080.
2. Hirsch IB, Bode BW, Garg S, Lane WS, Sussman A, Hu P, Santiago OM, Kolaczynski JW; the Insulin Aspart CSII/MDI Comparison Study Group: Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in type 1 diabetic patients previously treated with CSII. Diabetes Care 2005;28: 533-538.
3. Weissberg-Benchell J, Antisdel-Lomaglio J, Seshadri R: Insulin pump therapy: a meta-analysis. Diabetes Care 2003;26: 1079-1087.
4. Graff MH, Rubin RR, Walker EA: How diabetes specialists treat their own diabetes: findings from a study of the ADA and AADE membership. Diabetes Educ 2000;46:460-467.
5. Pickup J, Mattock M, Kerry S: Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections. BMJ 2002;324:705.
6. Pickup JC, Renard E: Long-acting insulin analogs versus insulin pump therapy for the treatment of type 1 and type 2 diabetes. Diabetes Care 2008;31(Suppl 2):S140-S145.
7. Bolli GB, Kerr D, Thomas R, Torlone E, Sola-Gazagnes A, Vitacolonna E, Selam JL, Home PD: Comparison of a multiple daily insulin injection regimen (basal once-daily glar-gine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) in type 1 diabetes: a randomized open parallel multicenter study. Diabetes Care 2009;32:1170-1176.
8. Bruttomesso D, Crazzolara D, Maran A, Costa S, Dal Pos M, Girelli A, Lepore G, Aragona M, Iori E, Valentini U, Del Prato S, Tiengo A, Buhr A, Trevisan R, Baritussio A: In type 1 diabetic patients with good glycaemic control, blood glucose variability is lower during continuous subcutaneous insulin infusion than during multiple daily injections with insulin glargine. Diabet Med 2008;25:326-332.
9. Garg SK, Walker AJ, Hoff HK, D'Souza AO, Gottlieb PA, Chase HP: Glycemic parameters with multiple daily injections using insulin glargine versus insulin pump. Diabetes Technol Ther 2004;6:9-15.
10. Ampudia-Blasco FJ: Assessment of the level of satisfaction and impact of a bolus calculator in patients with type 1 diabetes on CSII therapy. Infusystems USA 2007;4:17-20.
11. Zisser H, Robinson L, Bevier W, Dassau E, Ellingsen C, Doyle FJ, Jovanovic L: Bolus calculator: a review of four "smart" insulin pumps. Diabetes Technol Ther 2008;10:441-444.
12. Colino E, Alvarez MA, Carcavilla A, Alonso M, Ros P, Barrio R: Insulin dose adjustment when changing from multiple daily injections to continuous subcutaneous insulin infusion in the pediatric age group. Acta Diabetol 2009 Mar 25 [Epub ahead of print].
13. Monami M, Lamanna C, Marchionni N, Mannucci E: Continuous subcutaneous insulin infusion versus multiple daily insulin injections in type 1 diabetes: a meta-analysis. Acta Diabetol 2009 Jun 6 [Epub ahead of print].
14. Bode BW, Gross T, Ghegan MD, Davidson PC: Factors affecting the reduction of starting insulin dose in CSII. Diabetes 1999;48(Suppl 1):264.
15. Bode BW, Sabbah HT, Gross TM, Fredrickson LP, Davidson PC: Diabetes management in the new millennium using insulin pump therapy. Diabetes Metab Res Rev 2002; 18(Suppl 1):S14-S20.
16. Chase HP, Weimer C: Guidelines for basal insulin therapy with insulin pumps. Infusystems USA 2008;5:1-4.
17. Davidson PC, Hebblewhite HR, Steed RD, Bode BW: Analysis of guidelines for basal-bolus insulin dosing: basal insulin, correction factor, and carbohydrate-to-insulin ratio. Endocr Pract 2008;14:1095-1101.
18. Bode BW, Steed RD, Schleusener DS, Strange P: Switch to multiple daily injections with insulin glargine and insulin lispro from continuous subcutaneous insulin infusion with insulin lispro: a randomized, open-label study using a continuous glucose monitoring system. Endocr Pract 2005;11: 157-164.
19. Albright ES, Desmond R, Bell D: Efficacy of conversion from bedtime NPH insulin injection to once-or twice-daily injections of insulin glargine in type 1 diabetic patients using basal/bolus therapy. Diabetes Care 2004;27:632-633.
20. Ashwell SG, Gebbie J, Home PD: Twice-daily compared with once-daily insulin glargine in people with Type 1 diabetes using meal-time insulin aspart. Diabet Med 2006;23: 879-886.
21. Le Floch JP, Levy M, Mosnier-Pudar H, Nobels F, Laroche S, Gonbert S, Eschwege E, Fontaine P; Assessment of Detemir Administration in Progressive Treat-to-Target Trial (ADAPT) Study Group: Comparison of once-versus twice-daily administration of insulin detemir, used with mealtime insulin aspart, in basal-bolus therapy for type 1 diabetes: assessment of detemir administration in a progressive treat-to-target trial (ADAPT). Diabetes Care 2009;32:32-37.
22. Wang F, Carabino JM, Vergara CM: Insulin glargine: a systematic review of a long-acting insulin analogue. Clin Ther 2003;25:1541-1577.
23. Edelman S: The "Un-Tethered" Regimen (May 11, 2004). http://www.childrenwithdiabetes.com/clinic/untethered. htm (accessed November 29, 1009).
24. Campbell PJ, Bolli G, Cryer PE, Gerich JE: Pathogenesis of the dawn phenomenon in patients with insulin-dependent diabetes mellitus. N Engl J Med 1985;312:1473-1479.
25. Koivisto VA, Yki-Jarvinen H, Helve E, Pelkonen R: Patho-genesis and prevention of the dawn phenomenon in diabetic patients treated with CSII. Diabetes 1986;35:78-82.
26. Krieger DT, Allen W, Rizzo F, Krieger HP: Characterization of the normal temporal pattern of plasma corticosteroid levels. J Clin Endocrinol Metab 1971;32:266-284.
27. Francis AJ, Home PD, Hanning I, Alberti KGMM, Tunbridge WMG: Intermediate acting insulin given at bedtime: effect on blood glucose concentrations before and after breakfast. BMJ 1983;286:1173-1176.
28. Asplin CM, Faria AC, Carlsen EC, Vaccaro VA, Barr RE, Iranmanesh A, Lee MM, Veldhuis JD, Evans WS: Alterations in the pulsatile mode of growth hormone release in men and women with insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1989;69:239-245.
29. Winer LM, Shaw MA, Baumann G: Basal plasma growth hormone levels in man: new evidence for rhythmicity of growth hormone secretion. J Clin Endocrinol Metab 1990;70:1678-1686.
30. Bode BW, Gross TM, Thornton KR, Mastrototaro JJ: Continuous glucose monitoring used to adjust diabetes therapy improves glycosylated hemoglobin: a pilot study. Diabetes Res Clin Pract 1999;46:183-190.
31. Boland E, Monsod T, Delucia M, Brandt CA, Fernando S, Tamborlane WV: Limitations of conventional methods of self-monitoring of blood glucose: lessons learned from 3 days of continuous glucose sensing in pediatric patients with type 1 diabetes. Diabetes Care 2001;24:1858-1862.
32. Lumb AN, Gallen IW: Diabetes management for intense exercise. Curr Opin Endocrinol Diabetes Obes 2009;16:150-155.
33. Rabasa-Lhoret R, Bourque J, Ducros F, Chiasson JL: Guidelines for premeal insulin dose reduction for postprandial exercise of different intensities and durations in type 1 diabetic subjects treated intensively with a basal-bolus insulin regimen (ultralente-lispro). Diabetes Care 2001;24:625-630.
34. Brink S, Laffel L, Likitmaskul S, Liu L, Maguire AM, Olsen B, Silink M, Hanas R: Sick day management in children and adolescents with diabetes. Pediatr Diabetes 2009;10(Suppl 12):146-153.
35. Hirsch IB: Insulin analogues. N Engl J Med 2005;352:174-183.
36. Mudaliar SR, Lindberg FA, Joyce M, Beerdsen P, Strange P, Lin A, Henry RR: Insulin aspart (B28 Asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. Diabetes Care 1999;22:1501-1506.
37. Philbin R: Smart Pumps and Sports: Using Insulin On Board. 2005. http://www.childrenwithdiabetes.com/sports/iob. htm (accessed January 21, 2010).
38. O'Connell MA, Gilbertson HR, Donath SM, Cameron FJ: Optimizing postprandial glycemia in pediatric patients with type 1 diabetes using insulin pump therapy: impact of gly-cemic index and prandial bolus type. Diabetes Care 2008;31: 1491-1495.
39. Jones SM, Quarry JL, Caldwell-McMillan M, Mauger DT, Gabbay RA: Optimal insulin pump dosing and postprandial glycemia following a pizza meal using the Continuous Glucose Monitoring System. Diabetes Technol Ther 2005;7: 233-240.
40. Lane WS, Cochran EK, Jackson JA, Scism-Bacon JL, Corey IB, Hirsch IB, Skyler JS: High-dose insulin therapy: is it time for U-500 insulin? Endocr Pract 2009;15:71-79.
41. Raskin P, Bode BW, Marks JB, Hirsch IB, Weinstein RL, McGill JB, Peterson GE, Mudaliar SR, Reinhardt RR: Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes: a randomized, parallel-group, 24-week study. Diabetes Care 2003;26:2598-2603.
42. Guerra SM, Kitabchi AE: Comparison of the effectiveness of various routes of insulin injection: insulin levels and glucose response in normal subjects. J Clin Endocrinol Metab 1976; 42:869-874.
43. Frid A, Gunnarsson R, Guntner P, Linde B: Effects of accidental intramuscular injection on insulin absorption in IDDM. Diabetes Care 1988;11:41-45.
44. Vaag A, Pedersen KD, Lauritzen M, Hildebrandt P, Beck-Nielsen H: Intramuscular versus subcutaneous injection of unmodified insulin: consequences for blood glucose control in patients with type 1 diabetes mellitus. Diabet Med 1990;7: 335-342.
45. American Diabetes Association: Insulin administration. Diabetes Care 2004;27(Suppl 1):S106-S109.
46. Moghissi ES, Korytkowski MT, DiNardo M, Einhorn D, Hellman R, Hirsch IB, Inzucchi SE, Ismail-Beigi F, Kirkman MS, Umpierrez G: Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009;15:540-559.